What is the appropriate medical management for a patient who has been on montelukast for 14 days without cough improvement?

Discontinue Montelukast and Reassess the Underlying Cause of Cough

After 14 days of montelukast without cough improvement, the medication should be discontinued and a systematic diagnostic evaluation should be initiated to identify the true etiology of the cough. Montelukast is not a first-line therapy for chronic cough and its lack of response after 2 weeks strongly suggests either an incorrect diagnosis or that the cough is not leukotriene-mediated 1, 2.

Why Montelukast Has Failed

The evidence demonstrates that montelukast has limited and variable efficacy for cough:

• In cough variant asthma (CVA), montelukast shows benefit only in a subset of patients where leukotrienes are the primary pathogenic mechanism 3. A 2-week trial is sufficient to determine response 3, 4.

• In postinfectious cough, a high-quality randomized controlled trial definitively showed montelukast is not effective compared to placebo 5.

• Current guidelines position montelukast as an alternative or add-on controller, not preferred first-line therapy 1, 2, 6.

The lack of response after 14 days indicates this patient either does not have CVA, or has CVA that is not leukotriene-mediated and requires different treatment.

Immediate Next Steps

1. Determine Cough Duration and Classification

• Acute cough (<3 weeks): Consider postinfectious causes, upper respiratory infection, or pneumonia 7, 8
• Subacute cough (3-8 weeks): Most likely postinfectious 8
• Chronic cough (>8 weeks): Requires systematic evaluation for the three most common causes 8

2. Evaluate for the Three Most Common Causes of Chronic Cough

The evidence strongly supports that chronic cough is most commonly due to 8:

Upper Airway Cough Syndrome (UACS) - previously called postnasal drip:

• Look for: throat clearing, nasal discharge, sensation of postnasal drip
• Empiric trial: First-generation antihistamine/decongestant (e.g., brompheniramine with sustained-release pseudoephedrine) 8
• If no response, obtain sinus imaging to rule out chronic sinusitis 8

Asthma (including cough variant asthma):

• Perform spirometry with bronchodilator testing
• If spirometry is normal or near-normal (FEV1 >70% predicted), methacholine challenge testing is more sensitive and specific than bronchodilator reversibility 1, 8
• Critical point: A negative methacholine challenge excludes asthma but does not rule out steroid-responsive cough (eosinophilic bronchitis) 1

Gastroesophageal Reflux Disease (GERD):

• May present as isolated cough without typical reflux symptoms ("silent GERD") 8
• Empiric trial: Proton pump inhibitor twice daily for 8 weeks 1
• Consider adding H2 antagonist at night for complete acid suppression 1

3. If Asthma is Confirmed, Switch to Inhaled Corticosteroids

Inhaled corticosteroids (ICS) are superior to montelukast for controlling asthma-related cough 1, 8. The evidence shows:

• ICS demonstrate better control of daytime symptoms (SMD -0.12) and especially night-time symptoms (SMD -0.23) compared to montelukast 9
• For cough variant asthma specifically, inhaled corticosteroids are the recommended treatment 1, 2
• If the patient has documented CVA with airway hyperresponsiveness, initiate ICS following asthma management guidelines 1

Alternative for severe cases: If cough persists despite ICS, consider a 2-week trial of oral prednisolone 30 mg daily to determine if the cough is corticosteroid-responsive 1. If there is no response to this, an alternative diagnosis should be considered 1.

4. Consider Postinfectious Cough (if duration 3-8 weeks)

If the cough began after a respiratory infection and has persisted 3-8 weeks 8:

• First-line: Trial of inhaled ipratropium bromide (Grade B evidence) 8
• Second-line: If ipratropium fails and cough significantly affects quality of life, trial inhaled corticosteroids 8
• For severe paroxysms: Consider short course of oral prednisone 30-40 mg daily after ruling out UACS, asthma, and GERD 8
• Antibiotics have no role unless bacterial sinusitis or pertussis is suspected 8

Critical Pitfalls to Avoid

1. Do not continue montelukast beyond 2-4 weeks without documented response 3, 4. The drug either works quickly or doesn't work at all.

2. Do not assume the cough is asthma-related without objective testing. Spirometry and/or methacholine challenge are essential 1, 8.

3. Do not overlook eosinophilic bronchitis, which presents as isolated cough with normal spirometry and negative methacholine challenge but responds to inhaled corticosteroids 1. If available, induced sputum eosinophil count can help diagnose this.

4. Be aware of montelukast's neuropsychiatric risks 10, 6, 11, 12. The FDA has issued boxed warnings about depression, anxiety, sleep disturbances, and suicidal ideation, particularly in children and adolescents. This is another reason to discontinue if ineffective.

5. Multiple causes often coexist. Up to 62% of chronic cough patients have more than one contributing factor 8. Sequential or simultaneous treatment of multiple conditions may be necessary.

Specific Treatment Algorithm

Week 0-2: Patient has been on montelukast (current situation)

Week 2-4:

• Discontinue montelukast
• Obtain spirometry ± methacholine challenge
• Start empiric first-generation antihistamine/decongestant for UACS
• If spirometry shows obstruction or methacholine positive → start ICS

Week 4-8:

• If no improvement, add PPI twice daily for presumed GERD
• Continue ICS if asthma confirmed
• Consider sinus imaging if UACS treatment failed

Week 8-12:

• If still no improvement with combined therapy, refer to pulmonology for further evaluation including possible bronchoscopy, HRCT, or assessment for less common causes 1